Fundraising Fox
Immunocore
NASDAQ: IMCRAbingdon, Oxfordshire · Founded 2021 · United Kingdom corporation · 4 known investors
Find your way into Immunocore
Sign up to see every warm intro you have to Immunocore
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Immunocore team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Immunocore is a biotechnology company developing T cell receptor (TCR) based immunomodulating therapies for patients with cancer, infectious diseases, and autoimmune diseases.
Founders & leadership
BD
Brian Di DonatoChief Financial Officer
TS
Tina St. LegerChief Human Resources Officer2022–2026Tina St. Leger is Chief Human Resources Officer at Immunocore, a biotechnology company developing T cell receptor-based immunomodulating therapies. She has held HR leadership roles in pharmaceuticals and retail across developed and emerging markets, and holds a Bachelor of Science in Chemistry from the University of St. Andrews.
BJ
RP
Robert PerezNamed on SEC filing
PR
Peter RatcliffeNamed on SEC filing
SK
Siddharth KaulNamed on SEC filing
RH
Roy HerbstNamed on SEC filing
KP
Kristine PetersonNamed on SEC filing
TC
Travis CoyNamed on SEC filing
Board
JB
John BellChairman of the Board of Directors
Investors · 4
Reported raises · per SEC filings
Form D private placements$140M disclosed across 1 round · 2022
▶$140MraisedJul 2022 · 8 investors · BiotechnologyRule 506(b)
▶$140MraisedJul 2022 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Brian Di DonatoExecutive Officer
- John BellDirector
- Robert PerezDirector
- David BermanExecutive Officer
- Tina St. LegerExecutive Officer
- Peter RatcliffeDirector
- Siddharth KaulDirector
- Bahija JallalExecutive Officer, Director
- Roy HerbstDirector
- Kristine PetersonDirector
- Travis CoyDirector
- Offering amount
- $140M
- Amount sold
- $140M
- First sale
- Jul 2022
- Incorporated
- Corporation, United Kingdom, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
3 people who came through Immunocore went on to found or lead other companies.
Related companies · 5
Massive BioMassive Bio operates an AI-based platform that matches cancer patients with oncology clinical trials and provides concierge support throughout the trial process. It serves patients across the U.S., Canada, Latin America, and Europe, and works with pharma and CRO customers, patient advocacy organizations, and the National Cancer Institute's network of cancer centers.
AlumniAstraZeneca develops and markets pharmaceutical products, vaccines, and biologics across oncology, cardiovascular disease, respiratory and immunology, and rare disease areas, serving patients and healthcare providers globally.
CancerresearchukCancer Research UK funds research across discovery, detection, prevention and treatment of cancer to improve patient outcomes and extend survival. It operates as a research funder and scientific organization serving academic and clinical researchers.
Immune-Onc TherapeuticsImmune Onc is a biotechnology company developing medicines to treat patients with hard-to-treat cancers and autoimmune diseases, with expertise in translational medicine and clinical development.
BionityBionity.com is a German-language B2B trade portal for the life sciences, biotechnology, and pharmaceutical industries, offering news, trends, supplier directories, job listings, and lab and production solutions. Operated by LUMITOS AG, it serves professionals in industry, research, and science and provides online marketing services to reach this B2B audience.
Companies working in the same space as Immunocore.
Frequently asked questions
- What does Immunocore do?
- Immunocore is a biotechnology company developing T cell receptor (TCR) based immunomodulating therapies for patients with cancer, infectious diseases, and autoimmune diseases.
- Who are Immunocore's investors?
- Immunocore's investors include Avego BioScience Capital, General Atlantic, JDRF T1D Fund, Rosetta Capital Ltd..
- How much funding has Immunocore raised?
- Immunocore has disclosed $140M raised across 1 round.
- Where is Immunocore headquartered?
- Immunocore is headquartered in Abingdon, Oxfordshire.